Jun '23. Lutetium-177 PSMA for prostate cancer, current developments and challenges

home > Uitgaven > Jun '23. Lutetium-177 PSMA for prostate cancer, current developments and challenges

[¹⁷⁷Lu]Lu-PSMA has shown to be effective and safe in patients with metastatic castration resistant prostate cancer (mCRPC), leading to Food and Drugs Authorization (FDA) approval in the United States of America for [¹⁷⁷Lu]Lu-PSMA-617 in March 2022 and to European Medical Agency (EMA) approval in December 2022. In the Netherlands, [¹⁷⁷Lu]Lu-PSMA-I&T is reimbursed since August 2021 for the same indication. This illustrates that a lot has happened since our initial report on [¹⁷⁷Lu]Lu-PSMA in the previous therapy special edition of Tijdschrift voor Nucleaire Geneeskunde, five years ago. This review will summarize recent scientific developments on [¹⁷⁷Lu]Lu-PSMA radioligand therapy. The most notable and impactful prospective trials included the TheraP-, and VISIONtrial investigating [¹⁷⁷Lu]Lu-PSMA-617 in mCRPC patients. They will be discussed in more detail.